NLRP3炎症酶途径:这是甲胺的关键目标
Yasamin Hosseini1,2, Amirhossein Niknejad1,2, Ayeh Sabbagh Kashani1,2
1Faculty of Pharmacy, Department of Toxicology and Pharmacology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Inflammopharmacology
|March 5, 2025
概括
抗糖尿病药物梅特福明 (MET) 通过调节核酸结合的寡合化域,含有3 (NLRP3) 炎症酶通路的氨酸丰富的重复和皮林域,显示出潜在的抗炎作用,这表明它对炎症性疾病具有治疗效用.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 核酸结合的寡合化域,含有3 (NLRP3) 炎症体的氨酸丰富的重复和皮林域是炎症反应的关键调节器,涉及许多疾病.
- 细胞损伤和氧化应激触发了NLRP3的激活,从而释放出促炎性细胞因子.
- 广泛使用的抗糖尿病药物梅特福明 (MET) 具有已知的抗炎性质.
研究的目的:
- 审查现有证据,关于甲胺对NLRP3炎症酶通路的影响.
- 评估梅特福林在与NLRP3激活相关的疾病中的潜在治疗效用.
主要方法:
- 对研究梅特福林对NLRP3炎症组分和活性的影响的文献综述.
- 对梅特福林抗炎机制的临床前和临床数据的分析.
主要成果:
- 甲胺通过各种机制对NLRP3炎症酶激活产生抑制作用.
- 有证据表明,甲胺可以减轻NLRP3驱动的炎症,提供一种潜在的治疗策略.
结论:
- 梅特福林对NLRP3通路的调节支持其在治疗炎症疾病方面的考虑.
- 需要进一步的研究,以充分阐明甲胺的作用,并优化其在NLRP3介导疾病中的使用.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Oral Hypoglycemic Agents: Biguanides and Glitazones
151
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
151
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Glucagon-like Receptor Agonists
290
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
290
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Regulation of the Unfolded Protein Response
2.4K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.4K


